Inhibikase Therapeutics advances Parkinson’s disease treatment with risvodetinib clinical trials
Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical studies for risvodetinib (risvo), a potential disease-modifying therapy for Parkinson’s disease and related disorders. The study, published in the Journal of Parkinson’s Disease, marks a significant advancement in Parkinson’s disease treatment. The Phase 1 study evaluated the […]